CDK4/CDK6 Recombinant Rabbit Monoclonal Antibody (HL2323) | Invitrogen MA5-56640 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

CDK4/CDK6 Recombinant Rabbit Monoclonal Antibody (HL2323)

catalog :

MA5-56640

quantity :

100 uL

price :

US 479.00

clonality :

recombinant

host :

domestic rabbit

conjugate :

nonconjugated

clone name :

HL2323

reactivity :

human, mouse, rat

application :

western blot

product information

Product Type :

Antibody

Product Name :

CDK4/CDK6 Recombinant Rabbit Monoclonal Antibody (HL2323)

Catalog # :

MA5-56640

Quantity :

100 uL

Price :

US 479.00

Clonality :

Recombinant Monoclonal

Purity :

protein A

Host :

Rabbit

Reactivity :

Human, Mouse, Rat

Applications :

Western Blot: Assay-dependent

Species :

Human, Mouse, Rat

Clone :

HL2323

Isotype :

IgG

Storage :

-20 C, Avoid Freeze/Thaw Cycles

Description :

CDK4 (Cyclin-Dependent Kinase 4) and CDK6 (Cyclin-Dependent Kinase 6) are crucial regulators of the cell cycle, specifically involved in the transition from the G1 phase to the S phase. These kinases form complexes with D-type cyclins (Cyclin D1, D2, and D3), which are necessary for their activation. Once activated, CDK4 and CDK6 phosphorylate the retinoblastoma protein (RB1), leading to the release of E2F transcription factors that drive the expression of genes required for DNA synthesis and cell cycle progression. Dysregulation of CDK4 and CDK6 activity is a common feature in various cancers, as it can lead to uncontrolled cell proliferation. Consequently, CDK4 and CDK6 have become important targets in cancer therapy, with inhibitors such as palbociclib, ribociclib, and abemaciclib being developed and approved for the treatment of certain types of cancer, particularly hormone receptor-positive breast cancer. These inhibitors work by blocking the kinase activity of CDK4 and CDK6, thereby halting cell cycle progression and reducing tumor growth.

Immunogen :

Recombinant fragment of human CDK4 + CDK6.

Format :

Liquid

Applications w/Dilutions :

Western Blot: Assay-dependent